Analytical validation, pre-approval revenue, and business development for next-generation Multi Cancer Early Detection assay

Detecting cancer earlier improves patient outcomes and reduces the burden of cancer on patients, their families, healthcare systems, and the economy.

Proteotype is a startup company whose mission is to detect cancer earlier. Proteotype is developing the Enlighten (Registered Trademark) test, a groundbreaking test that can detect cancer at its earliest stages through advanced protein analysis. Enlighten is a next generation test which detects signals from multiple types of cancer via a single blood test which measures how the body's immune system is responding to the development of cancer. The advantages of this approach over nearest current state of the art approaches are that signals are stronger, rather than weaker, for earlier stages of disease.

The project will finance analytical validation and generation of technical documentation to enable regulatory approval of the standardised, manufactured Enlighten assay kit, enable the generation of early-revenue via helping other diagnostics companies analyse their samples, and perform business development work to ensure Proteotype attracts the level of private investment required for rapid Enlighten commercialisation in the UK and globally.